Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

NCT06637306 is registered in ClinicalTrials.gov with Rima Patel as lead sponsor.

NCT NCT06637306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06637306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Lead sponsor
Rima Patel
Phase
Phase 1
Overall status
Recruiting
Start date
March 5, 2025
Completion date
March 10, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced triple negative breast cancer, tnbc - triple-negative breast cancer